BidaskClub upgraded shares of Natera (NASDAQ:NTRA) from a sell rating to a hold rating in a research note released on Wednesday, BidAskClub reports.

NTRA has been the topic of a number of other reports. Zacks Investment Research downgraded shares of Natera from a hold rating to a sell rating in a research report on Thursday, March 21st. Piper Jaffray Companies upped their target price on shares of Natera from $23.00 to $28.00 and gave the company an overweight rating in a research report on Monday, June 10th. Finally, Canaccord Genuity restated a buy rating and set a $25.00 target price on shares of Natera in a research report on Monday, March 11th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Natera has an average rating of Buy and a consensus price target of $28.25.

Shares of NASDAQ NTRA opened at $24.76 on Wednesday. The stock has a market cap of $1.72 billion, a P/E ratio of -11.52 and a beta of 1.43. The company has a debt-to-equity ratio of 20.88, a quick ratio of 1.73 and a current ratio of 1.85. Natera has a 12-month low of $11.08 and a 12-month high of $29.62.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, May 9th. The medical research company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. Natera had a negative net margin of 49.33% and a negative return on equity of 699.31%. The company had revenue of $66.82 million for the quarter, compared to the consensus estimate of $66.40 million. On average, sell-side analysts forecast that Natera will post -2.17 earnings per share for the current fiscal year.

In other news, Chairman Matthew Rabinowitz sold 1,418 shares of the company’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $24.79, for a total value of $35,152.22. Following the completion of the sale, the chairman now directly owns 1,286,612 shares of the company’s stock, valued at approximately $31,895,111.48. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jonathan Sheena sold 1,033 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $24.79, for a total value of $25,608.07. Following the completion of the sale, the insider now directly owns 240,061 shares of the company’s stock, valued at $5,951,112.19. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 316,632 shares of company stock worth $6,507,731. Corporate insiders own 9.29% of the company’s stock.

Several hedge funds have recently made changes to their positions in NTRA. Great West Life Assurance Co. Can increased its stake in shares of Natera by 136.8% in the 4th quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock valued at $80,000 after acquiring an additional 3,420 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Natera by 14.5% in the 4th quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after acquiring an additional 736 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in shares of Natera by 6.7% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 11,485 shares of the medical research company’s stock valued at $160,000 after acquiring an additional 717 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of Natera by 827.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,899 shares of the medical research company’s stock valued at $163,000 after acquiring an additional 7,047 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its stake in shares of Natera by 431.9% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 11,867 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 9,636 shares during the last quarter. 80.32% of the stock is owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Article: What does a market perform rating mean?

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.